(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.
Celldex Therapeutics's earnings in 2024 is -$150,216,000.On average, 7 Wall Street analysts forecast CLDX's earnings for 2024 to be -$165,811,793, with the lowest CLDX earnings forecast at -$187,593,897, and the highest CLDX earnings forecast at -$149,809,967. On average, 5 Wall Street analysts forecast CLDX's earnings for 2025 to be -$201,116,566, with the lowest CLDX earnings forecast at -$223,389,199, and the highest CLDX earnings forecast at -$183,616,641.
In 2026, CLDX is forecast to generate -$231,012,272 in earnings, with the lowest earnings forecast at -$264,487,508 and the highest earnings forecast at -$197,537,036.